천식 마우스모델에서 Human Cytotoxic T Lymphocyte-associated Antigen 4-immunoglobulin (Hu.CTLA4-Ig) 융합단백의 기도 염증과 기도과민성 억제
Human Cytotoxic T Lymphocyte-associated Antigen 4-immunoglobulin Fusion Protein Inhibits Airway Inflammation and Hyperresponsiveness in a Murine Model of Asthma
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: CD4+ T helper cells which differentiate into the Th2 cells are crucial for the initiation and progression of allergic asthma. Human Cytotoxic T Lymphocyte- associated Antigen 4-immunoglobulin (CTLA4-Ig) has been widely used in order to block T-cell costimulation in an array of experimental animal models of T-cell-mediated diseases. Objective: To evaluate whether human CTLA4-Ig fusion protein inhibits airway inflammation in a murine model of OVA-induced asthma. Method: Six-weeks-old BALB/c mice were used and airway inflammation was induced by OVA. Human CTLA4-Ig fusion protein was administered intravenously before and after sensitization with OVA. Airway responsiveness to methacholine was measured after antigen challenge. Total IgE, OVA-specific IgE, IgG1 and IgG2a in serum samples were assessed by ELISA. Bronchoalveolar lavage (BAL) and lung section were also performed. Result: In mice which were treated with the human CTLA4-Ig fusion protein before and after sensitization with OVA, airway hyperresponsiveness and eosinophil count of BAL were markedly decreased. In mice which were treated with human CTLA4-Ig before sensitization with OVA, serum total IgE level were more significantly reduced than that of positive control mice. Peribronchial inflammatory cell infiltration was desreased by the treatment of human CTLA4-Ig before and after sensitization with OVA. Conclusion: These results suggest that human CTLA4-Ig fusion protein may inhibit eosinophilic airway inflammation and airway hyperresponsivness in OVA-sensitized and airway challenged mice. (Korean J Asthma Allergy Clin Immunol 2008;28:205-213)
Abstract
Background: CD4+ T helper cells which differentiate into the Th2 cells are crucial for the initiation and progression of allergic asthma. Human Cytotoxic T Lymphocyte- associated Antigen 4-immunoglobulin (CTLA4-Ig) has been widely used in order to block T-cell costimulation in an array of experimental animal models of T-cell-mediated diseases. Objective: To evaluate whether human CTLA4-Ig fusion protein inhibits airway inflammation in a murine model of OVA-induced asthma. Method: Six-weeks-old BALB/c mice were used and airway inflammation was induced by OVA. Human CTLA4-Ig fusion protein was administered intravenously before and after sensitization with OVA. Airway responsiveness to methacholine was measured after antigen challenge. Total IgE, OVA-specific IgE, IgG1 and IgG2a in serum samples were assessed by ELISA. Bronchoalveolar lavage (BAL) and lung section were also performed. Result: In mice which were treated with the human CTLA4-Ig fusion protein before and after sensitization with OVA, airway hyperresponsiveness and eosinophil count of BAL were markedly decreased. In mice which were treated with human CTLA4-Ig before sensitization with OVA, serum total IgE level were more significantly reduced than that of positive control mice. Peribronchial inflammatory cell infiltration was desreased by the treatment of human CTLA4-Ig before and after sensitization with OVA. Conclusion: These results suggest that human CTLA4-Ig fusion protein may inhibit eosinophilic airway inflammation and airway hyperresponsivness in OVA-sensitized and airway challenged mice. (Korean J Asthma Allergy Clin Immunol 2008;28:205-213)
참고문헌 (41)
- Azzawi M, "Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma", Am Rev Resp Dis, 142, pp.1407~1413 (1990)
- Wardlaw AJ, "Eosinophils and mast cells in bronchoalveolar lavage in mild asthma: relationship to bronchial hyperreactivity", Am Rev Resp Dis, 137, pp.62~69 (1989)
- Walker C, "Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage", Am Rev Resp Dis, 146, pp.109~115 (1992)
- Bmsselle GG, "Attenuation of allergic airway inflammation in IL-4 deficient mice", Clin Exp Allergy, 24, pp.73~80 (1994)
- Lukacs NW, "Interleukin-4 dependent pulmonary eosinophil infiltration in a murine model of asthma", Am J Respir Cell Mol Biol, 10, pp.526~532 (1994)
- Wills-Karp M, "Interleukin-13 in asthma pathogenesis", Immunol Re, 202, pp.175~190 (2004)
- Schwartz RH, "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7", BB1 in interleukin-2 production and immunotherapy, 1992, pp.71, 1065~1068
- Guinan EC, "Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity", Blood, 84, pp.3261~3282 (1994)
- Linsley PS, "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7", BB-I, 1990, pp.87, 5031~5035
- Linsley PS, "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation", J Exp Med, 173, pp.721~730 (1991)
- Linsley PS, "CTLA-4 is a second receptor for the B cell activation antigen B7", J Exp Med, 174, pp.561~569 (1991)
- Green JM, "CTLA-4 can function as a negative regulator of T cell activation", Immunity, 1, pp.405~413 (1994)
- "J Exp Med", 1995, 459~465
- Waterhouse P, "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4", Science, 70, pp.985~988 (1995)
- Tivol EA, "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4", Immunity, 3, pp.541~547 (1995)
- Wallace PM, "CTLA4-Ig treatment ameliorates the lethality of murine graft-versus host disease across major histocompatibility complex barriers", Transplantation, 58, pp.602~610 (1994)
- Waterhouse P, "Lymphoproliferative disorders with lethality in mice deficient in CTLA-4", Science, 270, pp.985~988 (1995)
- Linsley PS, "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule", Science, 257, pp.792~795 (1992)
- Lenschow DJ, "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig", Science, 257, pp.789~792 (1992)
- Krinzman SJ, "Inhibition of T cell costimulation abrogates airway hyperresponsiveness in murine model", J Clin Invest, 98, pp.2693~2699 (1996)
- Van Oosterhout AJM, "Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma", Am J Respir Cell Mol Biol, 17, pp.386~392 (1997)
- Keane-Myers A, "B7-CD28", CTLA-4 costimulatory pathways are the development of T helper cell 2-mediated responses to inhaled antigens, 1997, pp.158, 2042~2049
- Padrid PA, "CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1", Th2 subsets in a murine model of asthma, 1998, pp.18, 453~462
- Deurloo DT, "Van Oosterhout AJ. CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model", Am J Respir Cell Mol Biol, 25, pp.751~760 (2001)
- Jang SO, "Immunotherapeutic effects of CTLA4Ig fusion protein on murine EAE and GVHD", Immune Network, 3, pp.302~309 (2003)
- Neuhaus-Steinmetz U, "Sequential development of airway hyperresponsiveness and acute airway obstruction in a mouse model of allergic inflammation", Int Arch Allergy Immunol, 121, pp.57~67 (2000)
- Ohara J, "Interleukin-4 is required to generate and sustain in vivo IgE responses", J lmmunol, 141, pp.2335~2341 (1988)
- Gett AV, "Cell division regulated the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation", Proc Natl Acad Sci USA, 95, pp.9488~9493 (1998)
- Corry DB, "Differential effects of blockade of CD28-B7 on the development of Thl or Th2 effector cells in experimental Leishmaniasis", J Immunol, 153, pp.4142~4148 (1994)
- Calcimaro F, "CTLA-4-Ig regulates tryptophan catabolism in vivo", Nat Immunol, 3, pp.985~987 (2002)
- Fallarino F, "Modulation of tryptophan catabolism by regulatory T cells", Nat Immunol, 4, pp.1206~1212 (2003)
- David HM, "Ligation of B7-1", B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells, 2004, pp.172, 4100~4110
- Claire NM, "Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells", Eur J Immunol, 32, pp.2888~2896 (2002)
- David HM, "Ligation of B7-1", B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells, 2004, pp.172, 4100~4110
- Andrew LM, "Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4- mediated induction of indoleamine 2,3 dioxygenase", Int Immunol, 16, pp.1391~1401 (2004)
- Nianqiao G, "Negative costimulatory molecules: the proximal of regulatory T cells?", Med Hypo, 67, pp.841~847 (2006)
- Hathcock KS, "Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function", J Exp Med, 180, pp.631~640 (1994)
- Van Gool SW, "CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?", Res Immunol, 146, pp.183~206 (1995)
- Abrams JR, "CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris", J Clin Invest, 103, pp.1243~1252 (1999)
- Kosuge H, "Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible costimulator and cytotoxic T-lymphocyte antigen 4 pathway", Transplantation, 75, pp.1374~1379 (2003)
- Gavett SH, "Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia", Am J Respir Cell Mol Biol, 10, pp.587~593 (1994)
